Hormonal
Lifestyle interventions (diet and exercise) combined with GLP-1 receptor agonists (GLP-1RAs) may mitigate gastrointestinal side effects and enhance weight loss, though their efficacy requires confirmation via randomized controlled trials.
If you are taking a GLP-1RA, do not abandon lifestyle changes. Focus on dietary strategies like smaller, lower-fat meals to manage nausea and other side effects. This may help you stay on the medication longer and potentially achieve greater weight loss, although more research is needed to confirm these benefits.
Lifestyle interventions that may potentially mitigate the side effects of GLP-1RA treatment and enhance weight loss are discussed here. The efficacy of such interventions awaits confirmation with well-designed randomized controlled trials.
Why this rating
The paper is a review article summarizing observational data and mechanistic hypotheses, explicitly stating that RCTs are needed.
Source
Opportunities to optimize lifestyle interventions in combination with <scp>glucagon‐like peptide</scp> ‐1‐based therapy
Satya Dash · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15829
More from this paper
- Newer GLP-1RAs achieve average weight loss of 15% or greater, but a substantial number of patients fail to achieve even 5% weight loss, and weight loss is lower in older adults, males, and those with type 2 diabetes.Good
- Weight loss of 20% or higher with newer GLP-1RAs raises concerns for nutritional deficiency and sarcopenia, necessitating monitoring similar to post-bariatric surgery care.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →